Showing 3821-3830 of 4902 results for "".
Allergan Commemorates 25th Anniversary of the First Two Approved Uses of BOTOX® (onabotulinumtoxinA)
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/allergan-commemorates-25th-anniversary-of-the-first-two-approved-uses-of-botox-onabotulinumtoxina-/19136/Allergan, Inc. (NYSE: AGN) today announced the launch of a video recognizing the physician pioneers and patient communities who contributed to the development of BOTOX® (onabotulinumtoxinA), one of the most recognized pharmaceutical brands in the United States. The video kicks off a year-long campaiDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine.Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaDermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologiNew Drugs in Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-drugs-in-psoriasis/20933/The last two years have seen a number of new drugs approved to treat psoriasis—from targeted biologics to new topicals.Get Ready: The Biosimilars Are Here
https://practicaldermatology.com/topics/psoriasis/get-ready-the-biosimilars-are-here/20662/Recent developments mean that biosimilars are finally hitting the US market.The “Aged Microenvironment”: New Understandings of Melanoma Spread and Aggression
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-aged-microenvironment-new-understandings-of-melanoma-spread-and-aggression/20863/New research sheds light on pathways through which melanoma may become more aggressive.Recent Developments
https://practicaldermatology.com/topics/practice-management/recent-developments-49/24006/Currents
https://practicaldermatology.com/topics/practice-management/currents/21161/A Closer Look at Cibinqo for AD Management
https://practicaldermatology.com/topics/atopic-dermatitis/a-closer-look-at-cibinqo-for-ad-management/23664/Oral JAK inhibitors offer rapid onset of efficacy and some flexibility in the management of moderate to severe eczema.